New biomarkers of disease activity may help better vet investigational therapies aimed at slowing the insidious neurodegeneration seen in primary progressive multiple sclerosis.
The data shows that changes in neuropathy impairment scores using nerve conduction studies may forecast which patients will respond better to treatment.
An 8 year old boy with genetically confirmed neurofibromatosis type 1 presents with first generalized seizure.